Head-To-Head Analysis: Endonovo Therapeutics (OTCMKTS:ENDVD) and Synaptogenix (NASDAQ:TAOX)

Synaptogenix (NASDAQ:TAOX) and Endonovo Therapeutics (OTCMKTS:ENDVD) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Volatility and Risk

Synaptogenix has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.

Profitability

This table compares Synaptogenix and Endonovo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-240.92%	-150.03%
Endonovo Therapeutics	-6,075.54%	N/A	-279.35%

Earnings & Valuation

This table compares Synaptogenix and Endonovo Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	N/A	N/A	-$12.77 million	($20.16)	-0.19
Endonovo Therapeutics	$170,000.00	0.00	-$400,000.00	($10.00)	N/A

Endonovo Therapeutics has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Endonovo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

10.3% of Synaptogenix shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Synaptogenix and Endonovo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1	0	0	0	1.00
Endonovo Therapeutics	0	0	0	0	0.00

Given Endonovo Therapeutics’ higher probable upside, analysts plainly believe Endonovo Therapeutics is more favorable than Synaptogenix.

Summary

Endonovo Therapeutics beats Synaptogenix on 7 of the 12 factors compared between the two stocks.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.